Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991918 | 0.91 | ALDH1A1 (0.34) | MEN1GAAKMT2A | |
| SCHEMBL21992653 | 0.89 | TAS2R14 (0.37) | BACE1SMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL21992650 | 0.89 | KDM4E (0.34) | SMN1; SMN2MEN1GAAMAPTKMT2A | |
| SCHEMBL21992644 | 0.85 | MTNR1A (0.41) | BACE1MTNR1AMTNR1BTP53MEN1 | |
| SCHEMBL21991885 | 0.84 | ALDH1A1 (0.43) | SMN1; SMN2MTNR1AMTNR1BTP53MEN1 | |
| SCHEMBL21991890 | 0.84 | BACE1 (0.39) | BACE1MEN1KMT2A | |
| SCHEMBL21991908 | 0.84 | MTNR1A (0.50) | SMN1; SMN2MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL21991868 | 0.82 | GAA (0.42) | MTNR1AMTNR1BGAAKMT2A | |
| SCHEMBL23606053 | 0.80 | KMT2A (0.41) | MTNR1AMTNR1BMEN1GAAMAPT | |
| SCHEMBL21991306 | 0.80 | BACE1 (0.37) | BACE1MTNR1AMTNR1BTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BACE1 1133/4885SMN1; SMN2 3122/4885MTNR1A 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.